Amneal Pharmaceuticals, Inc. and Strides Pharma Science Limited announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023. Icosapent ethyl acid soft gel capsules 0.5g and 1g is an ethyl ester of eicosapentaenoic acid (EPA) that is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (= 500 mg/dL) hypertriglyceridemia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.76 USD | +8.86% | +15.16% | +11.37% |
May. 03 | Truist Securities Raises Amneal Pharmaceuticals' Price Target to $9 From $7, Maintains Buy Rating | MT |
May. 03 | Drugmaker Amneal agrees to $270 million U.S. opioid settlement | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
886.6 INR | -1.14% | +1.12% | 977M | ||
6.76 USD | +8.86% | +15.16% | 2.09B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.37% | 2.09B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- AMRX Stock
- News Amneal Pharmaceuticals, Inc.
- Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules